U.S. Chemicals Stock News

We'd be surprised if Oil States International, Inc. ( NYSE:OIS ) shareholders haven't noticed that the Independent...

Even if it's not a huge purchase, we think it was good to see that Brian Roney, the President & CEO of Presurance...

FitLife Brands, Inc.'s ( NASDAQ:FTLF ) earnings announcement last week didn't impress shareholders. However, our...

Even if it's not a huge purchase, we think it was good to see that Junhua Wu, the Co-Founder of Baozun Inc...

If you are wondering whether Synopsys at around US$397.90 is priced for opportunity or already reflects high expectations, the key is to focus on what current valuation metrics are actually saying. The stock has seen a mixed run, with a 0.4% return over the last 7 days, a 9.0% decline over the past 30 days, a 17.2% decline year to date, but a 4.3% gain over the past year. These moves sit against a backdrop of ongoing interest in semiconductor design tools, AI related software and broader...

JPMorgan Chase (NYSE:JPM) has joined Project Glasswing, a new alliance with major tech and cybersecurity firms focused on tackling global cyber risks with next generation AI. The collaboration brings together JPMorgan Chase, Amazon, Microsoft, Apple, Google, and Anthropic to build AI models that can identify and defend against software vulnerabilities. Project Glasswing aims to address rising AI driven cyber threats to critical digital infrastructure across finance and the broader...

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire German biotech Tubulis, adding next generation antibody drug conjugate technologies to its oncology pipeline. The deal includes Tubulis' clinical stage ADC assets and platforms, which will form a dedicated ADC research unit within Gilead. The acquisition aims to broaden Gilead's cancer treatment portfolio as it manages patent expiries and revenue pressure in other areas. Gilead Sciences, trading at around $138.8, has seen a 14.1% return...

In early April 2026, RBC Capital Markets reported that Hanover Insurance Group’s earnings growth is likely to slow, with 2025 expected to be the peak through 2027 as catastrophe losses normalize, pricing spreads moderate, and macroeconomic uncertainty weighs on the outlook. An interesting aspect of the report is management’s continued conservative reserving stance in challenging areas like Commercial Auto Liability, which may influence how investors assess future risk and capital...

If you are wondering whether Universal Technical Institute at around US$36.29 is priced for opportunity or already reflects the story you are buying into, this article walks through what the current valuation is actually indicating. The stock has returned 0.5% over the last 7 days, 3.7% over the last 30 days and 46.1% year to date, with a 39.1% return over the last year and a very large gain over 5 years. Recent coverage around Universal Technical Institute has focused on its role in the...

Dillard's (DDS) has introduced Cyd Morris x Gianni Bini, an exclusive limited-edition capsule collection with designer Cydney Morris. This move could interest investors watching how curated collaborations influence customer traffic and brand differentiation. See our latest analysis for Dillard's. Dillard's recent Cyd Morris x Gianni Bini launch comes as the share price sits at US$574.95, with short term share price returns weaker but a very large 5 year total shareholder return indicating...

Wondering if Credo Technology Group Holding at US$106.79 is still offering value after a strong run, or if you might be late to the party. The stock has seen very mixed recent returns, with a 13.8% gain over the last 7 days, a 2.8% decline over the last 30 days, a 25.4% decline year to date, and a 202.5% return over the past year. These swings have kept Credo on many watchlists, as investors react to ongoing developments around the company and the wider semiconductor space. Recent coverage...

If you are wondering whether Marriott International at around US$330.93 is offering value or asking you to pay up, you are not alone. It is a question worth unpacking carefully. The stock has returned 1.2% over the last 7 days, 2.2% over 30 days, 5.6% year to date, 58.2% over 1 year, 108.0% over 3 years and 131.0% over 5 years, so the current price reflects a long stretch of strong share performance. Recent coverage has focused on Marriott International's position within the broader travel...

If you are wondering whether Cummins at around US$556.78 is still offering value or already pricing in a lot of optimism, you are asking the right question. The stock has seen returns of 3.5% over the last 7 days, 3.3% over the last 30 days, 6.7% year to date, 112.3% over 1 year, 159.4% over 3 years and 140.9% over 5 years, which naturally raises questions about growth potential and changing risk perceptions. Recent attention around Cummins has focused on its role as a key industrial name in...

Tempus AI (TEM) is back in focus after announcing ALERT trial results showing its AI driven electronic health record alerts improved timely evaluations and valve interventions for patients with aortic stenosis and mitral regurgitation. See our latest analysis for Tempus AI. The ALERT trial news lands as the share price tells a mixed story, with a 3.5% 7 day share price return set against a 30 day share price return of 10.4% and a 90 day share price return of 32.9%. The 1 year total...

If you are wondering whether Sonoco Products at around US$54.06 is priced attractively or asking too much for future potential, you are in the right place. The stock has been relatively steady over the past week with a 0.1% decline. The 1 year return of 39.4% and year to date return of 21.8% suggest the share price has already moved a long way for current holders. Recent news around Sonoco Products has focused on its position in the packaging sector and how investors are viewing its long...

Cyber.AI launch puts Accenture (ACN) at the center of AI security and dividend timing Accenture (ACN) has launched Cyber.AI, a Claude powered security solution aimed at continuous AI driven cyber operations, just as the stock approaches an ex dividend date that may focus investors on both income and innovation. See our latest analysis for Accenture. The Cyber.AI launch and upcoming dividend arrive after a tougher stretch for the stock, with a 30 day share price return of 8.23% and a 1 year...

AbbVie is launching Humira on the TrumpRx platform at an 86% discount as part of a new White House agreement to improve drug accessibility and reduce prices. The move marks a significant change in how one of the most widely used autoimmune drugs is priced and distributed to patients in the US. This corporate action extends AbbVie’s role beyond product development into direct collaboration with federal policy on affordable medication. For investors tracking AbbVie, ticker NYSE:ABBV, the...

In early April 2026, a prior ruling by the Third U.S. Circuit Court of Appeals allowed online betting platform Kalshi to operate in New Jersey, opening the door to additional online wagering activity in a key regulated market. This legal shift could expand the addressable online betting landscape for operators such as Boyd Gaming, which already participates in digital gaming and may find new partnership or product avenues as the regulatory perimeter widens. We’ll now examine how expanded New...

Ellington Financial expanded its credit exposure, including non-QM loans, reverse mortgages through Longbridge, and CLOs. The company completed its largest unsecured notes offering to date, adding funding capacity for balance sheet growth. Management is using the expanded balance sheet to support originations and distributable earnings that fund dividends. For anyone tracking NYSE:EFC, the latest moves matter more than a routine dividend headline. The stock trades at $12.05, with a 1 year...

Wingstop launched a limited-time Citrus Mojo flavor across the US, targeting spring and summer dining occasions. The company introduced an exclusive nationwide Sprite Loco Lime beverage, available only at Wingstop locations. These menu additions aim to draw guests into stores and digital channels during the warmer months. For investors watching NasdaqGS:WING, this product update adds a fresh data point beyond recent focus on valuation and franchise growth. The share price currently sits at...

Baker Hughes secured its first order to deploy NovaLT gas turbine technology in South America. The company will supply advanced gas compression units for a major Argentine pipeline linking the Vaca Muerta formation to new LNG export capacity. This contract highlights demand for high efficiency, lower emissions turbomachinery in regional gas and LNG infrastructure. Baker Hughes, trading on NasdaqGS:BKR, sits at a share price of $61.25 with a value score of 5. The stock has seen a 29.9%...

Wondering if Brown-Forman is attractively priced or just looks that way on the surface? This article walks through the key signals that matter for anyone assessing the current share price. The stock recently closed at US$26.55, with returns of 0.4% over 7 days and 5.1% over 30 days. The 1-year return is a 12.8% decline, and the 3-year and 5-year returns are declines of 55.1% and 59.3%, respectively. Recent news flow around Brown-Forman has centered on its position as a long-established...

Wondering whether Snowflake's current share price still makes sense for you, or if the market has moved ahead of the fundamentals? Snowflake shares last closed at US$149.24, with a 1% decline over 7 days, a 17.3% decline over 30 days, and a 31.1% decline year to date, while the 1 year return stands at 11.8% and the 3 year and 5 year returns are 7.2% and 37.3% decline respectively. These mixed returns over different time frames suggest that sentiment around Snowflake has shifted more than...

Regulatory clarity and analyst upgrade shift focus back to Intellia’s pipeline The FDA’s decision to lift clinical holds on Intellia Therapeutics (NTLA) MAGNITUDE and MAGNITUDE-2 trials, after ruling a prior patient death unlikely related to its therapy, has refocused attention on the stock. See our latest analysis for Intellia Therapeutics. At a share price of US$13.55, Intellia has bounced in the near term, with a 1-day share price return of 1.88%, a 7-day return of 5.69% and a 90-day gain...